Toxicity profile of small-molecule IAP antagonist GDC-0152 is linked to TNF-α pharmacology

Toxicological Sciences

Volumn 131, Issue 1, 2013, Pages 247-258

  Erickson, Rebecca I ^a   Tarrant, Jacqueline ^a   Cain, Gary ^a   Lewin Koh, Sock Cheng ^a   Dybdal, Noel ^a   Wong, Harvey ^a   Blackwood, Elizabeth ^a   West, Kristina ^a   Steigerwalt, Ronald ^a   Mamounas, Michael ^a   Flygare, John A ^a   Amemiya, Kenjie ^a   Dambach, Donna ^a   Fairbrother, Wayne J ^a   Diaz, Dolores ^a  

^a GENENTECH INC   (United States)

Author keywords

IAP; MCP 1; Systemic inflammatory response; TNF

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTINEOPLASTIC AGENT; GAMMA INTERFERON; GDC 0152; INTERLEUKIN 5; MONOCYTE CHEMOTACTIC PROTEIN 1; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CELL INFILTRATION; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG EXPOSURE; EXPERIMENTAL DOG; FEMALE; HISTOPATHOLOGY; LUNG TOXICITY; MALE; NEUTROPHIL COUNT; NONHUMAN; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; RAT; RECTUM TEMPERATURE; SPECIES DIFFERENCE; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; TISSUE NECROSIS; TOXIC HEPATITIS; TOXICITY TESTING;

ANIMALS; ANTINEOPLASTIC AGENTS; CHEMOKINES; CYCLOHEXANES; DOGS; FEMALE; INHIBITOR OF APOPTOSIS PROTEINS; LIVER; LUNG; MALE; PYRROLES; RATS; RATS, SPRAGUE-DAWLEY; SPECIES SPECIFICITY; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; TOXICITY TESTS; TUMOR NECROSIS FACTOR-ALPHA;

CANIS FAMILIARIS; INTRACISTERNAL A-PARTICLES; RATTUS;

EID: 84872398313     PISSN: 10966080     EISSN: 10960929     Source Type: Journal    
DOI: 10.1093/toxsci/kfs265     Document Type: Article

References (42)

1. Augello, C., Caruso, L., Maggioni, M., Donadon, M., Montorsi, M., Santambrogio, R., Torzilli, G., Vaira, V., Pellegrini, C., Roncalli, M., et al. (2009). Inhibitors of apoptosis proteins (IAPs) expression and their prognostic significance in hepatocellular carcinoma. BMC Cancer 9, 125.
2. Aydinli, M., and Bayraktar, Y. (2007). Budd-Chiari syndrome: Etiology, pathogenesis and diagnosis. World J. Gastroenterol. 13, 2693-2696.
3. Brobmann, G. F., Ulano, H. B., Hinshaw, L. B., and Jacobson, E. D. (1970). Mesenteric vascular responses to endotoxin in the monkey and dog. Am. J. Physiol. 219, 1464-1467.
4. Cavanagh, D., Rao, P. S., Sutton, D. M., Bhagat, B. D., and Bachmann, F. (1970). Pathophysiology of endotoxin shock in the primate. Am. J. Obstet. Gynecol. 108, 705-722.
5. Ceron, J. J., Eckersall, P. D., and Martýnez-Subiela, S. (2005). Acute phase proteins in dogs and cats: Current knowledge and future perspectives. Vet. Clin. Pathol. 34, 85-99.
6. Craddock, C. G. (1978). Corticosteroid-induced lymphopenia, immunosuppression, and body defense. Ann. Intern. Med. 88, 564-566.
7. Eichacker, P. Q., Hoffman, W. D., Farese, A., Banks, S. M., Kuo, G. C., MacVittie, T. J., and Natanson, C. (1991). TNF but not IL-1 in dogs causes lethal lung injury and multiple organ dysfunction similar to human sepsis. J. Appl. Physiol. 71, 1979-1989.
8. Flygare, J. A., Beresini, M., Budha, N., Chan, H., Chan, I. T., Cheeti, S., Cohen, F., Deshayes, K., Doerner, K., Eckhardt, S. G., et al. (2012). Discovery of a potent small-molecule antagonist of inhibitor of apoptosis (IAP) proteins and clinical candidate for the treatment of cancer (GDC-0152). J. Med. Chem. 55, 4101-4113.
9. Flygare, J. A., and Fairbrother, W. J. (2010). Small-molecule pan-IAP antagonists: A patent review. Expert Opin. Ther. Pat. 20, 251-267.
10. Gamble, J. R., Harlan, J. M., Klebanoff, S. J., and Vadas, M. A. (1985). Stimulation of the adherence of neutrophils to umbilical vein endothelium by human recombinant tumor necrosis factor. Proc. Natl. Acad. Sci. U.S.A. 82, 8667-8671.
11. Gérain, J., Liénard, D., Ewalenko, P., and Lejeune, F. J. (1992). High serum levels of TNF-alpha after its administration for isolation perfusion of the limb. Cytokine 4, 585-591.
12. Graham, M. A., Mitsuuchi, Y., Burns, J., Chunduru, S., Benetatos, C., McKinlay, M., Weng, D., Wick, M. J., Tolcher, A. W., Papadopoulos, K., et al. (2011). Phase 1 PK/PD analysis of the Smac-mimetic TL32711 demonstrates potent and sustained cIAP1 suppression in patient PBMCs and tumor biopsies. AACR-NCI-EORTC International Conference Abstracts A25.
13. Gyrd-Hansen, M., and Meier, P. (2010). IAPs: From caspase inhibitors to modulators of NF-kappaB, inflammation and cancer. Nat. Rev. Cancer 10, 561-574.
14. Hamano, T., Tong, V., Mutai, M., Hayashi, M., and Tanaka, E. (2002). Kupffer cell-mediated cytotoxicity induced by lipopolysaccharide0111:B4 is greater in dogs than in rats and monkeys. J. Toxicol. Sci. 27, 1-9.
15. Han, J., Brown, T., and Beutler, B. (1990). Endotoxin-responsive sequences control cachectin/tumor necrosis factor biosynthesis at the translational level. J. Exp. Med. 171, 465-475.
16. Hersh, E. M., Metch, B. S., Muggia, F. M., Brown, T. D., Whitehead, R. P., Budd, G. T., Rinehart, J. J., Crawford, E. D., Bonnet, J. D., and Behrens, B. C. (1991). Phase II studies of recombinant human tumor necrosis factor alpha in patients with malignant disease: A summary of the Southwest Oncology Group experience. J. Immunother. 10, 426-431.
17. Infante, J. R., Dees, E. C., Burris, H. A., Zawei, L., Sager, J. A., Stevenson, C., Clarke, K., Dhuria, S., Porter, D., Sen, S. K., et al. (2010). A phase I study of LCL161, an oral IAP inhibitor, in patients with advanced cancer. AACR 101st Annual Meeting 2010 Abstract, April 2010, Washington, DC.
18. Kilbourn, R. G., Gross, S. S., Jubran, A., Adams, J., Griffith, O. W., Levi, R., and Lodato, R. F. (1990). NG-methyl-L-arginine inhibits tumor necrosis factor-induced hypotension: Implications for the involvement of nitric oxide. Proc. Natl. Acad. Sci. U.S.A. 87, 3629-3632.
19. Koj, A., and Jura, J. (2003). Complex analysis of genes involved in the inflammatory response: Interleukin-1-induced differential transcriptome of cultured human hepatoma HepG2 cells. Acta Biochimica Polonica 50(3), 573-582.
20. Koukourakis, M. I., Kambouromiti, G., Pitsiava, D., Tsousou, P., Tsiarkatsi, M., and Kartalis, G. (2009). Serum C-reactive protein (CRP) levels in cancer patients are linked with tumor burden and are reduced by anti-hypertensive medication. Inflammation 32, 169-175.
21. Laukens, B., Jennewein, C., Schenk, B., Vanlangenakker, N., Schier, A., Cristofanon, S., Zobel, K., Deshayes, K., Vucic, D., Jeremias, I., et al. (2011). Smac mimetic bypasses apoptosis resistance in FADD- or caspase-8-deficient cells by priming for tumor necrosis factor α-induced necroptosis. Neoplasia 13, 971-979.
22. Lazar, I., Yaacov, B., Shiloach, T., Eliahoo, E., Kadouri, L., Lotem, M., Perlman, R., Zakay-Rones, Z., Panet, A., and Ben-Yehuda, D. (2010). The oncolytic activity of Newcastle disease virus NDV-HUJ on chemoresistant primary melanoma cells is dependent on the proapoptotic activity of the inhibitor of apoptosis protein Livin. J. Virol. 84, 639-646.
23. Legare, D. J., and Lautt, W. W. (1987). Hepatic venous resistance site in the dog: Localization and validation of intrahepatic pressure measurements. Can. J. Physiol. Pharmacol. 65, 352-359.
24. Mahoney, D. J., Cheung, H. H., Mrad, R. L., Plenchette, S., Simard, C., Enwere, E., Arora, V., Mak, T. W., Lacasse, E. C., Waring, J., et al. (2008). Both cIAP1 and cIAP2 regulate TNFalpha-mediated NF-kappaB activation. Proc. Natl. Acad. Sci. U.S.A. 105, 11778-11783.
25. Miura, K., Fujibuchi, W., Ishida, K., Naitoh, T., Ogawa, H., Ando, T., Yazaki, N., Watanabe, K., Haneda, S., Shibata, C., et al. (2011). Inhibitor of apoptosis protein family as diagnostic markers and therapeutic targets of colorectal cancer. Surg. Today 41, 175-182.
26. Natanson, C., Eichenholz, P. W., Danner, R. L., Eichacker, P. Q., Hoffman, W. D., Kuo, G. C., Banks, S. M., MacVittie, T. J., and Parrillo, J. E. (1989). Endotoxin and tumor necrosis factor challenges in dogs simulate the cardiovascular profile of human septic shock. J. Exp. Med. 169, 823-832.
27. Netea, M. G., Kullberg, B. J., and Van der Meer, J. W. (2000). Circulating cytokines as mediators of fever. Clin. Infect. Dis. 31(Suppl. 5), S178-S184.
28. Oppenheim, J. J., Rossio, J. L., and Gearing, A. J. H. (1993). Clinical Applications of Cytokines: Role in Pathogenesis, Diagnosis, and Therapy. Oxford University Press, New York, NY.
29. Roberts, N. J., Zhou, S., Diaz, L. A., Jr., and Holdhoff, M. (2011). Systemic use of tumor necrosis factor alpha as an anticancer agent. Oncotarget 2, 739-751.
30. Sikic, B. I., Eckhardt, S. G., Gallant, G., Burris, H. A., Camidge, D. R., Colevas, A. D., Jones, S. F., Messersmith, W. A., Wakelee, H. A., Li, H., et al. (2011). Safety, pharmacokinetics (PK), and pharmacodynamics (PD) of HGS1029, an inhibitor of apoptosis protein (IAP) inhibitor, in patients (Pts) with advanced solid tumors: Results of a phase I study. J. Clin. Oncol. 29, 3008 (Abstract).
31. Tarrant, J. M. (2010). Blood cytokines as biomarkers of in vivo toxicity in preclinical safety assessment: Considerations for their use. Toxicol. Sci. 117, 4-16.
32. Tracey, K. J., Beutler, B., Lowry, S. F., Merryweather, J., Wolpe, S., Milsark, I. W., Hariri, R. J., Fahey, T. J., 3rd, Zentella, A., and Albert, J. D. (1986). Shock and tissue injury induced by recombinant human cachectin. Science 234, 470-474.
33. Vandenabeele, P., Galluzzi, L., Vanden Berghe, T., and Kroemer, G. (2010). Molecular mechanisms of necroptosis: An ordered cellular explosion. Nat. Rev. Mol. Cell Biol. 11, 700-714.
34. Varfolomeev, E., Blankenship, J. W., Wayson, S. M., Fedorova, A. V., Kayagaki, N., Garg, P., Zobel, K., Dynek, J. N., Elliott, L. O., Wallweber, H. J., et al. (2007). IAP antagonists induce autoubiquitination of c-IAPs, NF-kappaB activation, and TNFalpha-dependent apoptosis. Cell 131, 669-681.
35. Varfolomeev, E. E., and Ashkenazi, A. (2004). Tumor necrosis factor: An apoptosis JuNKie? Cell 116, 491-497.
36. Varfolomeev, E. E., and Vucic, D. (2011). Inhibitor of apoptosis proteins: Fascinating biology leads to attractive tumor therapeutic targets. Future Oncol. 7, 633-648.
37. Vince, J. E., Wong, W. W., Khan, N., Feltham, R., Chau, D., Ahmed, A. U., Benetatos, C. A., Chunduru, S. K., Condon, S. M., McKinlay, M., et al. (2007). IAP antagonists target cIAP1 to induce TNFalpha-dependent apoptosis. Cell 131, 682-693.
38. Vucic, D., Dixit, V. M., and Wertz, I. E. (2011). Ubiquitylation in apoptosis: A post-translational modification at the edge of life and death. Nat. Rev. Mol. Cell Biol. 12, 439-452.
39. Walley, K. R., Hebert, P. C., Wakai, Y., Wilcox, P. G., Road, J. D., and Cooper, D. J. (1994). Decrease in left ventricular contractility after tumor necrosisalpha infusion in dogs. J. Appl. Physiol. 76, 1060-1067.
40. Watterson, C., Lanevschi, A., Horner, J., and Louden, C. (2009). A comparative analysis of acute-phase proteins as inflammatory biomarkers in preclinical toxicology studies: Implications for preclinical to clinical translation. Toxicol. Pathol. 37, 28-33.
41. Wong, H., Budha, N. R., West, K., Blackwood, E., Ware, J., Yu, R., Darbonne, W. C., Gould, S. E., Steigerwalt, R., Erickson, R., et al. (Forthcoming). Dogs are more sensitive to antagonists of inhibitor of apoptosis (IAP) proteins than rats and humans: A translational toxcicokinetic/toxicodynamic analysis. Toxicol. Sci.
42. Zhu, A. X., Duda, D. G., Ancukiewicz, M., di Tomaso, E., Clark, J. W., Miksad, R., Fuchs, C. S., Ryan, D. P., and Jain, R. K. (2011). Exploratory analysis of early toxicity of sunitinib in advanced hepatocellular carcinoma patients: Kinetics and potential biomarker value. Clin. Cancer Res. 17, 918-927.